INZY News and Press, Inozyme Pharma Inc. From 08/01/23

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the closing of its underwritten public off...

2023-07-28 05:01:44 ET Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, Inozyme Pharma ( NASDAQ: INZY ) priced an underwritten public offering of 12.5M shares at a p...

BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the pricing of an underwritten public offe...

2023-07-27 17:40:45 ET Gainers: SIGA Technologies  ( NASDAQ: SIGA ) +26% . View ( VIEW ) +17% . Roku ( ROKU ) +9% . First Solar ( FSLR ) +7% . BJ's Restaurants ( BJRI ) +6% . Losers: Sleep Number ( SNBR ) -...

BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it is commencing an underwritten publ...

2023-07-26 10:37:58 ET Gainers: ABVC BioPharma ( ABVC ) +50% . Benitec Biopharma ( BNTC ) +45% . Tilray Brands ( TLRY ) +23% . Teladoc Health ( TDOC ) +21% . Biodexa Pharmaceuticals ( BDRX ) +8% . Losers: Carmell Ther...

2023-07-26 09:11:45 ET Summary Tech stock momentum have experienced significant downturns over the past week, with Nasdaq-100 constituents glowing red. There are ample suggestions of sector rotation in play, which a variety of analytical filters also bear out. Spreads between ...

- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients - - ENERGY-3 pivotal trial in pediatric patients expected to initiate in October 2023, topline data expected to be reported in mi...

2023-07-21 15:00:10 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

– Conference call and webcast to be held on July 26, 2023, at 8am ET – BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developi...